>Go!

Teva Agreement

Teva Agreement

Allergan and Teva announced on July 27, 2015, that the companies had entered into a definitive agreement under which Teva Pharmaceutical Industries Ltd. will acquire Allergan's global generic pharmaceuticals business for $40.5 billion.  Allergan will receive $33.75 billion in cash and $6.75 billion in Teva stock.  

In addition, Allergan retains 50 percent of Teva's future economics from generic lenalidomide (Revlimid®).  The transaction has been unanimously approved by the Boards of Directors of Allergan and Teva and is strongly supported by the management teams of both companies.

Teva Form 8-K (pdf)

Allergan - Teva Investor Presentation (pdf) 

Transaction-Related Press Releases

27 JUL 2015
Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion


Investor Contact:

+1 (862) 261-7152
investorrelations@allergan.com


Media Contact:

Mark Marmur
+1 (862) 261-8030
Media.Relations@allergan.com


Forward-Looking Statement
Statements contained in this communication that refer to future events or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.